Literature DB >> 33045047

Atrial fibrillation and the risk of ischaemic strokes or intracranial haemorrhages: comparisons of the catheter ablation, medical therapy, and non-atrial fibrillation population.

Min Kim1, Hee Tae Yu1, JongYoun Kim1, Tae-Hoon Kim1, Jae-Sun Uhm1, Boyoung Joung1, Moon-Hyoung Lee1, Hui-Nam Pak1.   

Abstract

AIMS: Although atrial fibrillation (AF) catheter ablation (AFCA) is an effective rhythm control strategy, there is limited data on whether ischaemic stroke (IS) or intracranial haemorrhage (ICH) decreases after AFCA compared with medical therapy or non-AF population. We explored the IS and ICH risk after AFCA or medical therapy in the AF population and matched non-AF population. METHODS AND
RESULTS: We compared 1629 patients with AFCA (Yonsei AF ablation cohort), 3258 with medical therapy [Korean National Health Insurance (NHIS) database], and 3258 non-AF subjects (NHIS database) following a 1:2:2 propensity score matching. All AFCA patients underwent regular rhythm follow-ups for 51 ± 29 months. Among the AFCA group, the incidence rate ratio (IRR) of ISs was significantly higher in patients with sustained AF recurrences after the last ablation (0.87%) than in those remaining in sinus rhythm (0.24%, P = 0.017; log rank P = 0.003). The IRR of ISs was significantly higher in the medical therapy (1.09%) than AFCA (0.30%, P < 0.001, log rank P < 0.001 vs. medical therapy) or non-AF groups (0.34%, P < 0.001, log rank P < 0.001 vs. medical therapy; P = 0.673, log rank P = 0.874 vs. AFCA). The IRR of ICHs was 0.17% in the medical therapy, 0.06% in the AFCA (P = 0.023, log rank P = 0.042 vs. medical therapy), and 0.12% in the non-AF group (P = 0.226, log rank P = 0.241 vs. medical therapy; P = 0.172, log rank P = 0.193 vs. AFCA).
CONCLUSION: Post-procedural AF control influences the risk of ISs. Atrial fibrillation catheter ablation significantly reduces the risk of both ISs and ICHs to the extent of the non-AF population compared to the medical therapy. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author(s) 2020. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Atrial fibrillation; Catheter ablation; Intracranial haemorrhage; Ischaemic stroke

Year:  2021        PMID: 33045047     DOI: 10.1093/europace/euaa235

Source DB:  PubMed          Journal:  Europace        ISSN: 1099-5129            Impact factor:   5.214


  5 in total

1.  Ischemic Stroke in Non-Gender-Related CHA2DS2-VA Score 0~1 Is Associated With H2FPEF Score Among the Patients With Atrial Fibrillation.

Authors:  Min Kim; Hee Tae Yu; Tae-Hoon Kim; Dae-In Lee; Jae-Sun Uhm; Young Dae Kim; Hyo Suk Nam; Boyoung Joung; Moon-Hyoung Lee; Ji Hoe Heo; Hui-Nam Pak
Journal:  Front Cardiovasc Med       Date:  2022-02-08

2.  Incidence and Risk Factors for Residual Adverse Events Despite Anticoagulation in Atrial Fibrillation: Results From Phase II/III of the GLORIA-AF Registry.

Authors:  Wern Yew Ding; Deirdre A Lane; Dhiraj Gupta; Menno V Huisman; Gregory Y H Lip
Journal:  J Am Heart Assoc       Date:  2022-07-25       Impact factor: 6.106

3.  Impact of early ablation of atrial fibrillation on long-term outcomes: results from phase II/III of the GLORIA-AF registry.

Authors:  Menno V Huisman; Gregory Y H Lip; Wern Yew Ding; Peter Calvert; Dhiraj Gupta
Journal:  Clin Res Cardiol       Date:  2022-04-29       Impact factor: 6.138

4.  The Characteristics, Long-Term Outcomes, Risk Factors, and Antithrombotic Therapy in Chinese Patients With Atrial Fibrillation and Bioprosthetic Valves.

Authors:  Jiameng Ren; Yanmin Yang; Jun Zhu; Shuang Wu; Juan Wang; Han Zhang; Xinghui Shao
Journal:  Front Cardiovasc Med       Date:  2021-06-10

5.  Clinical Outcomes of Computational Virtual Mapping-Guided Catheter Ablation in Patients With Persistent Atrial Fibrillation: A Multicenter Prospective Randomized Clinical Trial.

Authors:  Yong-Soo Baek; Oh-Seok Kwon; Byounghyun Lim; Song-Yi Yang; Je-Wook Park; Hee Tae Yu; Tae-Hoon Kim; Jae-Sun Uhm; Boyoung Joung; Dae-Hyeok Kim; Moon-Hyoung Lee; Junbeom Park; Hui-Nam Pak
Journal:  Front Cardiovasc Med       Date:  2021-12-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.